Kidney Cancer Coverage From Every Angle
Advertisement
Advertisement

Toni K. Choueiri, MD, and Michael D. Staehler, MD, PhD, on RCC: Results From the SWITCH-II and SURTIME Trials

Posted: Wednesday, October 4, 2017

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Michael D. Staehler, MD, PhD, of the University of Munich, discuss study findings on sorafenib-pazopanib vs pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (mRCC); and immediate vs deferred cytoreductive nephrectomy in patients with synchronous mRCC receiving sunitinib.